JP2005533046A - 鎮痛薬の作用を増強するためにオピオイド鎮痛薬と併用するデバゼピドの使用 - Google Patents

鎮痛薬の作用を増強するためにオピオイド鎮痛薬と併用するデバゼピドの使用 Download PDF

Info

Publication number
JP2005533046A
JP2005533046A JP2004510798A JP2004510798A JP2005533046A JP 2005533046 A JP2005533046 A JP 2005533046A JP 2004510798 A JP2004510798 A JP 2004510798A JP 2004510798 A JP2004510798 A JP 2004510798A JP 2005533046 A JP2005533046 A JP 2005533046A
Authority
JP
Japan
Prior art keywords
devazepide
opioid
use according
analgesic
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004510798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533046A5 (enrdf_load_stackoverflow
Inventor
ジャクソン，カレン
Original Assignee
エムエル・ラボラトリーズ・パブリック・リミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エムエル・ラボラトリーズ・パブリック・リミテッド・カンパニー filed Critical エムエル・ラボラトリーズ・パブリック・リミテッド・カンパニー
Publication of JP2005533046A publication Critical patent/JP2005533046A/ja
Publication of JP2005533046A5 publication Critical patent/JP2005533046A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004510798A 2002-06-10 2003-06-10 鎮痛薬の作用を増強するためにオピオイド鎮痛薬と併用するデバゼピドの使用 Withdrawn JP2005533046A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0213198A GB0213198D0 (en) 2002-06-10 2002-06-10 Method of treatment
PCT/GB2003/002480 WO2003103679A1 (en) 2002-06-10 2003-06-10 Use of devazepide in combination with an opioid analgesic for potentiating the effect of the analgesic

Publications (2)

Publication Number Publication Date
JP2005533046A true JP2005533046A (ja) 2005-11-04
JP2005533046A5 JP2005533046A5 (enrdf_load_stackoverflow) 2006-06-01

Family

ID=9938219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004510798A Withdrawn JP2005533046A (ja) 2002-06-10 2003-06-10 鎮痛薬の作用を増強するためにオピオイド鎮痛薬と併用するデバゼピドの使用

Country Status (5)

Country Link
EP (1) EP1569654A1 (enrdf_load_stackoverflow)
JP (1) JP2005533046A (enrdf_load_stackoverflow)
AU (1) AU2003246888A1 (enrdf_load_stackoverflow)
GB (1) GB0213198D0 (enrdf_load_stackoverflow)
WO (1) WO2003103679A1 (enrdf_load_stackoverflow)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120562A1 (ja) 2007-04-02 2008-10-09 Toyo Boseki Kabushiki Kaisha 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法
WO2012118172A1 (ja) * 2011-03-03 2012-09-07 国立大学法人熊本大学 疼痛における中枢機能改善薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721746D0 (en) * 1997-10-15 1997-12-10 Panos Therapeutics Limited Compositions
GB0201367D0 (en) * 2002-01-22 2002-03-13 Ml Lab Plc Composition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120562A1 (ja) 2007-04-02 2008-10-09 Toyo Boseki Kabushiki Kaisha 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法
WO2012118172A1 (ja) * 2011-03-03 2012-09-07 国立大学法人熊本大学 疼痛における中枢機能改善薬
JP6032561B2 (ja) * 2011-03-03 2016-11-30 国立大学法人 熊本大学 疼痛における中枢機能改善薬

Also Published As

Publication number Publication date
AU2003246888A1 (en) 2003-12-22
GB0213198D0 (en) 2002-07-17
EP1569654A1 (en) 2005-09-07
WO2003103679A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
JP2001527554A (ja) 抗うつ薬とｎｍｄａレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法
WO2007005716A2 (en) Methods of treatment and compositions for use thereof
AU6836500A (en) Drug therapy of the restless leg syndrome
JP2009506080A (ja) 超低用量のα−２−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および／またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法
US20140350042A1 (en) Methods for treating pruritus
AU782523B2 (en) Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
Pirat et al. Ondansetron, orally disintegrating tablets versus intravenous injection for prevention of intrathecal morphine-induced nausea, vomiting, and pruritus in young males
KR101971412B1 (ko) 정맥 내 투여용 이부프로펜의 투여
EP1467718B1 (en) Method of treatment of a patient requiring analgesia
Tuttle Drug management of pain in cancer patients
KR20120106671A (ko) 혈중 화학 물질을 제거하기 위한 방법 및 투약 요법
US7923453B1 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
JP2005533046A (ja) 鎮痛薬の作用を増強するためにオピオイド鎮痛薬と併用するデバゼピドの使用
US20040043990A1 (en) Method of treatment
EP1492540B1 (en) The use of devazepide as analgesic agent
US20040167146A1 (en) Method of treatment
US20160213680A1 (en) Compositions and methods using flumazenil with opioid analgesics for treating pain and/or addiction, and with diversion and/or overdose mitigation
US20030139396A1 (en) Method of treatment
US20080125414A1 (en) Method of Treatment
US8012990B2 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
BR112019027889A2 (pt) método de tratamento e formas de dosagem do mesmo
US20040198723A1 (en) Method of treatment
US8222267B2 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
EP0966286B1 (en) Attenuation of opioid tolerance by inhibiting inducible nitric oxide synthase pathways in the treatment of pain
WO2003080066A1 (en) Use of devazepide for the treatment of constipation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060407

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060623

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090213